Last reviewed · How we verify
NCT05615415
Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 (PASC) Using TSPO Positron Emission Tomography (PET) and MRI
trial testing PET Tracer in Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 Infection in 30 participants. Participants enrolled and being followed up; not accepting new ones.
31 December 2026
Quick facts
| Lead sponsor | NYU Langone Health |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 15 February 2022 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- PET Tracer — full drug profile →
- MRI Tracer — full drug profile →
- 3T PET/MRI
Conditions studied
- Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 Infection — all drugs for Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 Infection →
Sponsor
NYU Langone Health — full company profile →
Who can join
Adults 18 to 50, any sex, with Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The overarching goal of this study is to develop PET/MR techniques for the diagnosis of neuropsychiatric post-acute sequelae (PASC) of SARS-CoV-2. The central hypothesis is that immunological and cerebrovascular dysfunction after acute SARS-CoV-2 infections mediate neuropsychiatric PASC (NP-PASC).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Long COVID: Complications, Underlying Mechanisms, and Treatment Strategies.
Zadeh FH, Wilson DR, Agrawal DK. · · 2023 · cited 36× · PMID 37388279 · DOI 10.26502/ami.93650103
Verify or expand the search:
- PubMed search for NCT05615415
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PET Tracer
Trials testing the same drug.
- NCT07302763 — Four-Timepoint Multi-tracer PET Imaging to Characterize Metastatic prOstate Cancer Heterogeneity · NA · recruiting
Other NYU Langone Health trials
Trials by the same sponsor.
- NCT07214519 — Permanent Supportive Housing Overdose Prevention-2 Study · NA · not yet recruiting
- NCT05558267 — Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease · NA · not yet recruiting
- NCT06637852 — Sexual and Urinary Function Improvement for Cancer Survivors · NA · not yet recruiting
- NCT06236087 — Overdose Prevention Centers and Behavioral Health · not yet recruiting
- NCT06462027 — Packed Red Blood Cell Transfusion During Cardiac Arrest · Phase 1 · suspended
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05615415 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by NYU Langone Health
- Last refreshed: 28 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05615415.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing